Ohio State Discoveries Highlight Colon Cancer Prevention, Melanoma Spread Prediction, and Innovative Drug Therapies at AACR 2025

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are unveiling groundbreaking advancements in cancer research at the prestigious American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. Their collection of studies spotlights innovative targeted therapies, novel biomarkers, and lifestyle interventions that may significantly shift current cancer treatment paradigms and prevention strategies across multiple cancer types.

Among the most promising developments presented is a novel dihydroorotate dehydrogenase (DHODH) inhibitor therapy aimed at combating small cell lung cancer (SCLC) and other advanced solid tumors. This class of drug, exemplified by the candidate HOSU-53 (known preclinically as JBZ-001), acts by disrupting the enzyme DHODH, which plays a pivotal role in de novo pyrimidine biosynthesis—a critical metabolic process fueling rapid cancer cell proliferation. Given the notorious aggressiveness of SCLC and its poor long-term response to conventional chemotherapies, this targeted approach offers a refined molecular mechanism to potentially curb tumor growth. Early preclinical investigations demonstrated significant tumor cell growth inhibition, justifying the launch of phase I human trials currently recruiting patients whose tumors have exhibited resistance to standard treatments.

In parallel, the OSUCCC – James team introduces compelling data about predictive biomarkers in early-stage melanoma. Approximately one-fifth of melanomas that initially present as localized have the dismal prognosis of metastasizing to vital organs such as the liver, lungs, or brain. Using a 31-gene expression profile (31-GEP), researchers have elucidated stratification tools capable of distinguishing patients at the highest risk of dissemination. This molecular diagnostic innovation may revolutionize clinical surveillance by directing intensified monitoring and timely therapeutic interventions to those with aggressive disease signatures, potentially improving survival outcomes among melanoma patients.

Another focus of intense scrutiny is glioblastoma multiforme (GBM), the deadliest primary brain tumor with less than 10% five-year survival. Investigators examined the modulatory effects of radiation therapy (RT) and temozolomide (TMZ) chemotherapy on proteasome subunit alpha 7 (PSMA7), a proteolytic protein overexpressed in GBM cells and correlated with poor prognosis. Their findings revealed a radiation dose-dependent suppression of PSMA7 expression, suggesting PSMA7 as a promising therapeutic target. Combining RT with PSMA7 inhibitors could amplify tumoricidal effects, addressing the urgent need for novel treatments in GBM therapy.

The burgeoning epidemic of obesity-related cancers also garners attention, specifically with regard to endometrial carcinoma—the most common gynecologic malignancy in the United States. A nuanced study explored the role of extracellular vesicles (EVs), which are nano-scale membrane-bound particles secreted by adipocytes in obese individuals. These EVs appear to mediate oncogenic signaling by ferrying pro-tumorigenic proteins from adipose and uterine tissues, creating a microenvironment conducive to malignant transformation. This intriguing link between metabolic dysregulation and cancer biology highlights EVs as potential molecular targets for interventions aiming to prevent or attenuate obesity-driven endometrial tumorigenesis.

Metformin, a widely prescribed anti-diabetic agent, was recently evaluated for its therapeutic implications in colorectal cancer, particularly in tumors harboring KRAS mutations. These mutations confer aggressive phenotypes and resistance to many therapies. In vitro experiments demonstrated that metformin selectively induces cell cycle arrest in colorectal cancer cells bearing the mutant KRAS gene, while sparing cells with wild-type KRAS. Gene expression analyses elucidated alterations in pathways governing cell proliferation and apoptosis, underscoring metformin’s multi-parametric impact. These insights suggest repurposing metformin as an adjuvant or chemopreventive agent in genetically defined patient populations.

Lifestyle modifications remain a cornerstone in cancer prevention, and OSUCCC – James investigators presented preliminary findings from the BEFIT exercise trial targeting individuals at elevated risk for lung cancer. This 12-week intervention evaluates whether structured physical activity can attenuate systemic inflammation and modulate the respiratory and gut microbiomes, thereby reducing carcinogenic risk. The study cohort—characterized by high body mass indices, significant smoking histories, and demographic diversity—exhibited remarkable adherence and tolerability. Such integrative approaches complement ongoing beverage-based microbiome studies, reinforcing the potential of non-pharmacologic strategies in reducing lung cancer incidence.

Beyond the laboratory and clinical observations, the OSUCCC – James community celebrates the election of Dr. Electra Paskett to the AACR Fellows Academy, an honor recognizing her trailblazing contributions to cancer prevention, screening, and survivorship. Her work centers on underserved and high-risk groups, particularly for breast, cervical, and colorectal cancers, and includes defining the chemopreventive effects of aspirin and improving quality of life post-chemotherapy with duloxetine. This accolade underscores the center’s holistic commitment to innovation that transcends basic science to profoundly impact patient care.

Taken together, these multifaceted investigations from OSUCCC – James exemplify how targeted molecular therapies, predictive diagnostics, and lifestyle interventions converge to forge a new frontier in oncology. The integration of biochemical pathways with clinical applications, alongside an emphasis on community and population health, signals a future where precision medicine and prevention are inextricably linked. As these studies progress towards broader clinical validation, their implications promise to resonate across cancer centers globally, inspiring new paradigms in improving patient outcomes.

The translation of laboratory discoveries to clinical settings is evidenced not only in ongoing clinical trials such as the phase I evaluation of HOSU-53 for advanced solid tumors and lymphomas but also in innovative biomarker development and mechanistic insights. Researchers continue to delve into tumor biology at the molecular level, optimizing therapeutic combinations that sensitize tumors to existing treatments while unveiling novel targets. The meticulous characterization of tumor microenvironments and systemic influences like obesity and lifestyle factors further accentuates the complexity and necessity of multidisciplinary approaches in cancer care.

Moreover, the commitment to patient-centered research is reflected in the careful design of clinical interventions with high patient adherence and safety profiles, as demonstrated in the BEFIT exercise study among high-risk lung cancer populations. This reinforces that advances in oncology are not solely dependent on molecular breakthroughs but also hinge upon improving healthcare delivery models and preventive strategies that encompass behavioral science and community engagement.

As OSUCCC – James researchers continue to disseminate their work at forums such as the AACR Annual Meeting, they exemplify the dynamic interplay between discovery, clinical translation, and societal impact. Their collective efforts forge a path toward diminishing cancer’s global burden through innovative science and compassionate care.

—

Subject of Research: Targeted therapies, biomarkers, and preventive strategies across multiple cancer types including small cell lung cancer, melanoma, glioblastoma, endometrial, and colorectal cancers.

Article Title: Ohio State Researchers Unveil Pioneering Cancer Therapies and Diagnostics at AACR 2025 Annual Meeting

News Publication Date: April 25-30, 2025

Web References:
https://cancer.osu.edu/

Home

https://cancer.osu.edu/for-cancer-researchers/at-conferences/aacr

Keywords: Cancer research; targeted therapy; small cell lung cancer; melanoma; glioblastoma; endometrial cancer; colorectal cancer; DHODH inhibitor; KRAS mutation; metformin; extracellular vesicles; exercise intervention.

Tags: AACR Annual Meeting 2025cancer treatment paradigmscolon cancer prevention strategiesdihydroorotate dehydrogenase inhibitor therapyinnovative drug therapieslifestyle interventions for cancer preventionmelanoma spread predictionnovel cancer biomarkersOhio State cancer researchphase I clinical trialssmall cell lung cancer treatmenttargeted cancer therapies